Pamidronate disodium salt hydrate, >=95% (NMR), solid

Pamidronate disodium salt hydrate, >=95% (NMR), solid

Stock Code: 3573527
Manufacturer Part No: P2371-10MG
Order Now for 21 day delivery
£154.61 (exc VAT) per 10MG
Quantity: - +

Biochem/physiol Actions


Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase (IC50 = 200 nM).


Pamidronate disodiumhas the ability to block Wnt and ?-catenin signaling, which modulates the osteogenic differentiation in bone marrow mesenchymal stem cells (BMMSCs). It can also reduce bilirubin-impaired apoptosis and helps to develop dentinogenic dysfunction of stem cells from human deciduous teeth.


Features and Benefits


This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.


This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.


Packaging


10, 100 mg in glass bottle

Colourwhite
Quality Level100
mp300 °C
InChI keyTVQNUQCYOOJTMK-UHFFFAOYSA-L
InChI1S/C3H11NO7P2.2Na.H2O/c4-2-1-3(5,12(6,7)8)13(9,10)11;;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;;1H2/q;2*+1;/p-2
ManufacturerSIGMA-ALDRICH
Formsolid
Assay≥95% (NMR)

There are no downloads for this product.